Candel Therapeutics, Inc. Profile Avatar - Palmy Investing

Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase I…

Biotechnology
US, Needham [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Candel Therapeutics, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Candel Therapeutics, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Candel Therapeutics, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of CADL's Analysis
CIK: 1841387 CUSIP: 137404109 ISIN: US1374041093 LEI: - UEI: -
Secondary Listings
CADL has no secondary listings inside our databases.